SOURCE: Xechem International, Inc.

May 30, 2007 15:14 ET

Xechem Announces Addition of H. Scott English as Investor Relations Director and Ben White as Director of Finance and Accounting

NEW BRUNSWICK, NJ--(Marketwire - May 30, 2007) - Xechem International, Inc. (OTCBB: XKEM) today announced that it has hired H. Scott English as the Company's internal Director of Investor Relations and Benjamin S. White III as the Director of Finance and Accounting.

Scott is the Founder of The Halsey Group, LLC, an international business development firm which specializes in Biopharmaceutical/High Tech Sales and Public Relations. He has worked in several capacities for his client companies to successfully represent their interests and status to the client shareholder base.

Ben White was with Xechem in the early years as both a financial consultant and Controller and was the key financial manager during Xechem's IPO in 1994. Ben is a financial executive with over 30 years experience and has an established track record of revenue enhancements, cost reductions, cash management, fraud detections, and operations coordination/consolidation. He has served as a consultant with Moore Stephens, P.C. and Deloitte Touche USA LLP. He also served as a Regional Finance Director with PSE&G, a Fortune 200 Company, to continue post-acquisition analysis and integration of a $60M New York mechanical construction company. Mr. White continued in this position at the $500M mechanical construction division until its divestiture from PSEG.

Ben holds an MBA from Drexel University's LeBow College of Business, Philadelphia, which he completed in collaboration with Gallup's Leadership Capstone at Peking University in Beijing, China.

"I am very happy with our recent additions of Scott and Ben to the Xechem family," said company CEO and Chairman Dr. Ramesh Pandey. "From a Research and Development stage company to a company which has a product in the market and a number of other products in the pipe line, it is important that we build the company's structure. In taking this step we are building the confidence of our shareholders. Scott will play an important role in communicating and transmitting the right information to the shareholders." Mr. Stephen Burg, a long time Board of Directors member and a contact between the Company and shareholders until now said, "I sincerely welcome the addition of Scott to Xechem and hope with his past experience he will represent the Company in the best possible manner for all concerned. I am also happy that Ben White decided to come back, that shows his confidence in the future of the Company. I wish them well in their endeavors."

Mr. English is committed to a complete open door policy and encourages all shareholders to call any time for information He is also planning for a June 2007 release of the Xechem Monthly Newsletter, "Changing Tomorrow."

Please visit the Xechem website at and for more information, or for Investor Relations please contact H. Scott English at Phone: (732) 247-3300 ext. 37.

About Xechem

Xechem International is a development stage biopharmaceutical company working on Sickle Cell Disease (SCD), antidiabetic, antimalarial, antibacterial, antifungal, anticancer and antiviral (including AIDS) products from natural sources, including microbial and marine organisms. Its focus is on the development of proprietary technologies, including those used in the treatment of orphan diseases and other phyto-pharmaceuticals (natural herbal drugs). Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development of NICOSAN™ (to be marketed as HEMOXIN™ in the US and Europe). With the Nigerian regulatory approval now in hand, Xechem is working on the commercialization of the drug in Nigeria and the pursuit of US FDA and European regulatory approval. In addition to NICOSAN™, Xechem is also working on another sickle cell compound, 5-HMF, which it has licensed from Virginia Commonwealth University (VCU).


NICOSAN™ is an anti-sickling drug originally developed as NIPRISAN by the Nigerian scientists at the National Institute for Pharmaceutical Research and Development (NIPRD). In clinical studies conducted under NIPRD's auspices, the drug has shown to substantially reduce the degree of sickling of the red blood cells of those afflicted with the disease. While not a cure, the clinical trials have confirmed that the large majority of patients taking NICOSAN™ no longer experience sickle cell "crises" while on the medication, and even among those whose crises are not eliminated, the number and severity of the crises are substantially reduced. Through quality control/quality assurance (QC/QA) Xechem has standardized and verified the antisickling activity of the product, which is now called as NICOSAN™.

After the approval by the regulatory agency of Nigeria, National Agency for Food and Drug Administration and Control (NAFDAC), NICOSAN™ is being marketed in Nigeria since July 6th, 2006 on a limited basis. NICOSAN™ has Orphan Drug Designation in the US and EU countries.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks and uncertainties. Such risks include the risk that: (i) Xechem Nigeria will be unable to consummate the closing of its currently proposed bank financings; (ii) there could be delays and/or cost overruns in connection with the build out of Xechem Nigeria's pilot plant facility to a full scale commercial production facility; (iii) the Company and/or Xechem Nigeria could suffer significant dilution from the raising of additional capital until such point in time as they achieve cash flow break even status; (iv) doing business in Nigeria is subject to all of the risks of operation in a foreign country and associated political and regulatory risky and iv) operations of the Company could be disrupted due to the chronic limited availability of funds to meet ongoing obligations.

Contact Information

  • For further information contact:
    H. Scott English
    Director, Investor Relations
    (732) 247-3300 ext. 37